Kyverna reports Q1 net loss $39.7M; initiates rolling BLA for miv-cel in SPS

Kyverna Therapeutics, Inc.

• Cash, cash equivalents and marketable securities of $236.4M as of March 31, 2026; cash runway expected into 2028.
• Net loss of $39.7M ($0.66 per share) for Q1 2026; R&D expenses $30.1M, G&A $11.3M.
• Initiated rolling BLA submission for miv-cel in stiff person syndrome after positive pre-BLA meeting with FDA; completion expected Q4 2026.
• Primary analysis of KYSA-8 trial in SPS showed statistically significant durable benefit across all endpoints; 100% of patients free of immunotherapies at week 16.
• Appointed Nadia Dac as Chief Commercial Officer; enrollment ongoing in Phase 3 gMG trial.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.